Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis - PubMed (original) (raw)
Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis
T D Warner et al. Proc Natl Acad Sci U S A. 1999.
Erratum in
- Proc Natl Acad Sci U S A 1999 Aug 17;96(17):9666
Abstract
The beneficial actions of nonsteroid anti-inflammatory drugs (NSAID) can be associated with inhibition of cyclo-oxygenase (COX)-2 whereas their harmful side effects are associated with inhibition of COX-1. Here we report data from two related assay systems, the human whole blood assay and a modified human whole blood assay (using human A549 cells as a source of COX-2). This assay we refer to as the William Harvey Modified Assay. Our aim was to make meaningful comparisons of both classical NSAIDs and newer COX-2-selective compounds. These comparisons of the actions of >40 NSAIDs and novel COX-2-selective agents, including celecoxib, rofecoxib and diisopropyl fluorophosphate, demonstrate a distribution of compound selectivities toward COX-1 that aligns with the risk of serious gastrointestinal complications. In conclusion, this full in vitro analysis of COX-1/2 selectivities in human tissues clearly supports the theory that inhibition of COX-1 underlies the gastrointestinal toxicity of NSAIDs in man.
Figures
Figure 1
The effects of celecoxib (A), diclofenac (B), etodolac (C), ibuprofen (D), meloxicam (E), and nimesulide (F) on the activity of COX-1 (solid line), WBA-COX-2 (short dashed line), and WHMA-COX-2 (long dashed line). Results are expressed as percent of control and are represented as mean ± SEM. (n = 5–8).
Figure 2
The effects of diisopropyl fluorophosphate (A), L-745,337 (B), NS398 (C), and rofecoxib (D) on the activity of COX-1 (solid line), WBA-COX-2 (short dashed line), and WHMA-COX-2 (long dashed line). Results are expressed as percent of control and are represented as mean ± SEM. (n = 5–8).
Figure 3
Determinable log [IC80 ratio (WBA-COX-2/COX-1)] for all agents assayed (see Table 1). The “0 line” indicates equipotency, i.e., an IC80 ratio of 1. Italics indicate compounds with very low potency.
Figure 4
Analysis of the percent inhibition of COX-1 seen when COX-2 (WHMA) is inhibited by 80%. The dotted line indicates equiactivity, i.e., an 80% inhibition of COX-1.
Similar articles
- Gastrointestinal toxicity of non-steroidal anti-inflammatory drugs: the effect of nimesulide compared with naproxen on the human gastrointestinal tract.
Bjarnason I, Thjodleifsson B. Bjarnason I, et al. Rheumatology (Oxford). 1999 May;38 Suppl 1:24-32. doi: 10.1093/rheumatology/38.suppl_1.24. Rheumatology (Oxford). 1999. PMID: 10369403 Review. - Cyclooxygenase-2 inhibitors: a new class of anti-inflammatory agents that spare the gastrointestinal tract.
Masferrer JL, Isakson PC, Seibert K. Masferrer JL, et al. Gastroenterol Clin North Am. 1996 Jun;25(2):363-72. doi: 10.1016/s0889-8553(05)70252-1. Gastroenterol Clin North Am. 1996. PMID: 9229578 Review. - Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor.
Riendeau D, Percival MD, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D, Evans J, Falgueyret JP, Ford-Hutchinson AW, Gordon R, Greig G, Gresser M, Guay J, Kargman S, Léger S, Mancini JA, O'Neill G, Ouellet M, Rodger IW, Thérien M, Wang Z, Webb JK, Wong E, Chan CC, et al. Riendeau D, et al. Br J Pharmacol. 1997 May;121(1):105-17. doi: 10.1038/sj.bjp.0701076. Br J Pharmacol. 1997. PMID: 9146894 Free PMC article. - Up-regulation of cyclooxygenase-2 by inhibition of cyclooxygenase-1: a key to nonsteroidal anti-inflammatory drug-induced intestinal damage.
Tanaka A, Hase S, Miyazawa T, Takeuchi K. Tanaka A, et al. J Pharmacol Exp Ther. 2002 Mar;300(3):754-61. doi: 10.1124/jpet.300.3.754. J Pharmacol Exp Ther. 2002. PMID: 11861778 - [New NSAIDS: COX-1, COX-2, what about them?].
Peretz A. Peretz A. Rev Med Brux. 1998 Sep;19(4):A399-402. Rev Med Brux. 1998. PMID: 9805982 Review. French.
Cited by
- LC-MS/MS confirms that COX-1 drives vascular prostacyclin whilst gene expression pattern reveals non-vascular sites of COX-2 expression.
Kirkby NS, Zaiss AK, Urquhart P, Jiao J, Austin PJ, Al-Yamani M, Lundberg MH, MacKenzie LS, Warner TD, Nicolaou A, Herschman HR, Mitchell JA. Kirkby NS, et al. PLoS One. 2013 Jul 9;8(7):e69524. doi: 10.1371/journal.pone.0069524. Print 2013. PLoS One. 2013. PMID: 23874970 Free PMC article. - Decreased cyclooxygenase inhibition by aspirin in polymorphic variants of human prostaglandin H synthase-1.
Liu W, Poole EM, Ulrich CM, Kulmacz RJ. Liu W, et al. Pharmacogenet Genomics. 2012 Jul;22(7):525-37. doi: 10.1097/FPC.0b013e32835366f6. Pharmacogenet Genomics. 2012. PMID: 22513397 Free PMC article. - Effects of nabumetone and dipyrone on experimentally induced gastric ulcers in rats.
Yıldırım E, Sağıroğlu O, Kılıç FS, Erol K. Yıldırım E, et al. Inflammation. 2013 Apr;36(2):476-81. doi: 10.1007/s10753-012-9568-9. Inflammation. 2013. PMID: 23129452 - Mechanisms underlying the anti-inflammatory activity and gastric safety of acemetacin.
Chávez-Piña AE, McKnight W, Dicay M, Castañeda-Hernández G, Wallace JL. Chávez-Piña AE, et al. Br J Pharmacol. 2007 Nov;152(6):930-8. doi: 10.1038/sj.bjp.0707451. Epub 2007 Sep 17. Br J Pharmacol. 2007. PMID: 17876306 Free PMC article. - Salicylate Sodium Suppresses Monocyte Chemoattractant Protein-1 Production by Directly Inhibiting Phosphodiesterase 3B in TNF-α-Stimulated Adipocytes.
Zhang X, Gao Y, Liu Z, Li W, Kang Y, Li X, Xu Z, Peng C, Qi Y. Zhang X, et al. Int J Mol Sci. 2022 Dec 24;24(1):320. doi: 10.3390/ijms24010320. Int J Mol Sci. 2022. PMID: 36613764 Free PMC article.
References
- Vane J R. Nat New Biol. 1971;231:232–239. - PubMed
- Vane J R, Bakhle Y S, Botting R M. Annu Rev Pharmacol Toxicol. 1998;38:97–120. - PubMed
- Patrignani P, Panara M R, Greco A, Fusco O, Natoli C, Iacobelli S, Cipollone F, Ganci A, Créminon, Maclouf J, et al. J Pharmacol Exp Ther. 1994;271:1705–1712. - PubMed
- Brideau C, Kargman S, Liu S, Dallob A L, Ehrich E W, Rodger I W, Chan C-C. Inflamm Res. 1996;45:68–74. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Chemical Information
Molecular Biology Databases
Research Materials